Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity
Related Experiment Video
Updated: May 21, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Karl V Clemons1, Julie A Schwartz, David A Stevens
1California Institute for Medical Research, San Jose, California, USA. clemons@cimr.org
Abstract:
We have shown previously that high-dose lipid amphotericin preparations are not more efficacious than lower doses in aspergillosis. We studied toxicity, drug concentrations and localization, and quantitative infection concurrently, using a 4-day model of central nervous system (CNS) aspergillosis to assess early events. Mice given Aspergillus fumigatus conidia intracerebrally, under a cyclophosphamide immunosuppressive regimen, were treated for 3 days (AmBisome at 3 or 10 mg/kg of body weight, Abelcet at 10 mg/kg, amphotericin B deoxycholate at 1 mg/kg, caspofungin at 5 mg/kg, or voriconazole at 40 mg/kg). Sampling 24 h after the last treatment showed that AmBisome at 3 but not at 10 mg/kg, as well as Abelcet, caspofungin, and voriconazole, reduced brain CFU. All regimens reduced renal infection. Minor renal tubular changes occurred with AmBisome or Abelcet therapy, whereas heart, lung, and brain showed no drug toxicity. Amphotericin B tissue and serum concentrations did not correlate with efficacy. Endothelial cell activation (ICAM-1 and P-selectin in cerebral capillaries) occurred during infection. Amphotericin B derived from AmBisome and Abelcet localized in activated endothelium and from Abelcet in intravascular monocytes. In 10-day studies dosing uninfected mice, minor renal tubular changes occurred after AmBisome or Abelcet at 1, 5, or 10 mg/kg with or without cyclophosphamide treatment; nephrosis occurred only with Abelcet in cyclophosphamide-treated mice. Hepatotoxicity occurred with AmBisome and Abelcet but was reduced in cyclophosphamide-treated mice. Marked CFU reduction by AmBisome at 3 mg/kg occurred in association with relatively more intense inflammation. Abelcet renal localization appears to be a precursor to late nephrotoxicity. Hepatotoxicity may contribute to high-dose Abelcet and AmBisome failures. Our novel observation of endothelial amphotericin localization during infection may contribute to amphotericin mechanism of efficacy.
Insights
Lipid formulations of amphotericin B showed varying efficacy and toxicity in treating invasive aspergillosis. Drug concentrations did not correlate with effectiveness, but localization in activated endothelium was observed.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- High-dose lipid amphotericin B formulations are not proven more effective than lower doses for aspergillosis.
- Toxicity, drug concentrations, and localization require further investigation in early infection models.
Purpose of the Study:
- To assess the efficacy and toxicity of different amphotericin B formulations and other antifungals in a murine model of central nervous system aspergillosis.
- To investigate drug concentrations, tissue localization, and correlation with infection reduction.
Main Methods:
- Mice with intracerebral Aspergillus fumigatus infection and cyclophosphamide immunosuppression were treated with AmBisome, Abelcet, amphotericin B deoxycholate, caspofungin, or voriconazole.
- Brain and kidney colony-forming units (CFU) were quantified 24 hours after treatment.
- Drug toxicity, tissue concentrations, and endothelial cell activation markers were analyzed.
Main Results:
- AmBisome (3 mg/kg), Abelcet, caspofungin, and voriconazole reduced brain fungal burden; all regimens reduced kidney infection.
- Amphotericin B concentrations did not correlate with efficacy.
- Amphotericin B localized in activated endothelium and monocytes, with Abelcet showing renal and potential hepatotoxicity.
Conclusions:
- Lower doses of AmBisome (3 mg/kg) and other antifungals demonstrated efficacy in reducing fungal burden in CNS aspergillosis.
- Amphotericin B localization in endothelium may be key to its mechanism.
- Renal and hepatic toxicities are associated with specific lipid amphotericin B formulations, particularly at higher doses or with immunosuppression.
Related Concept Videos
Fungal Phylum Ascomycota
Antifungal Agents

